Cabaletta Bio Company
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
Estimated Revenue:
$1M to $10M
Headquarters:
Philadelphia, Pennsylvania, United States
Total Funding:
88000000
Last Funding Date:
2019
Founded Date:
2017-06-01
Technology:
['BioTech & HealthTech']
Industry:
Medical BioTech
Last Funding Type:
Series B
Employee Number:
11-50